Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Inhibitors of the mammalian target of rapamycin (MTOR) belong to a family of drugs with potent immunosuppressive, antiangiogenic, and antiproliferative properties. De novo or worsening proteinuria can occur during treatment with these agents, but the mechanism by which this occurs is unknown. We generated and characterized mice carrying a podocyte-selective knockout of the Mtor gene. Although Mtor was dispensable in developing podocytes, these mice developed proteinuria at 3 weeks and end stage renal failure by 5 weeks after birth. Podocytes from these mice exhibited an accumulation of the autophagosome marker LC3 (rat microtubule-associated protein 1 light chain 3), autophagosomes, autophagolysosomal vesicles, and damaged mitochondria. Similarly, human podocytes treated with the MTOR inhibitor rapamycin accumulated autophagosomes and autophagolysosomes. Taken together, these results suggest that disruption of the autophagic pathway may play a role in the pathogenesis of proteinuria in patients treated with MTOR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Podocyte-specific Mtor-knockout mice accumulated autophagosomes and autolysosomes within podocytes, and developed severe proteinuria and kidney failure shortly after birth, suggesting that mTOR-associated ALR might be important for podocyte health”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [49]
In the citing paper
“mice with lysosomal dysfunction in podocytes, induced by inducible podocyte-specific deletion of the genes encoding mTOR, prorenin or PI3K catalytic subunit type 3 (also known as VPS34) developed severe glomerulosclerosis and proteinuria”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Autophagy fights disease through cellular self-digestion
Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Termination of autophagy and reformation of lysosomes regulated by mTOR
Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi, N., Zhao, Y., Liu, Z., Wan, F., et al. (2010) · Nature · doi:10.1038/nature09076 · Cited by 1,544
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Self-citationEremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H.-P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,313
Self-citationHigh-efficiency deleter mice show that FLPe is an alternative to Cre-loxP
Rodríguez, C. I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A. F., & Dymecki, S. M. (2000) · Nature Genetics · doi:10.1038/75973 · Cited by 1,159
A Conditionally Immortalized Human Podocyte Cell Line Demonstrating Nephrin and Podocin Expression
Saleem, M. A., O’Hare, M. J., Reiser, J., Coward, R. J., Inward, C. D., Farren, T., Xing, C. Y., Ni, L., Mathieson, P. W., & Mundel, P. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133630 · Cited by 1,120
A Highly Efficient Recombineering-Based Method for Generating Conditional Knockout Mutations
Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013
Hartleben, B., Gödel, M., Meyer-Schwesinger, C., Liu, S., Ulrich, T., Köbler, S., Wiech, T., Grahammer, F., Arnold, S. J., Lindenmeyer, M. T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39492 · Cited by 721
mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 624
Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes
Narita, M., Young, A. R. J., Arakawa, S., Samarajiwa, S. A., Nakashima, T., Yoshida, S., Hong, S., Berry, L. S., Reichelt, S., Ferreira, M., et al. (2011) · Science · doi:10.1126/science.1205407 · Cited by 594
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Schena, F. P., Pascoe, M. D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D. C., Campistol, J. M., Racusen, L., Polinsky, M. S., Goldberg-Alberts, R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181927a41 · Cited by 583
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Grumati, P., Coletto, L., Sabatelli, P., Cescon, M., Angelin, A., Bertaggia, E., Blaauw, B., Urciuolo, A., Tiepolo, T., Merlini, L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2247 · Cited by 540
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
A New Method for Large Scale Isolation of Kidney Glomeruli from Mice
Takemoto, M., Asker, N., Gerhardt, H., Lundkvist, A., Johansson, B. R., Saito, Y., & Betsholtz, C. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64239-3 · Cited by 516
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes
Jones, N., Blasutig, I. M., Eremina, V., Ruston, J. M., Bladt, F., Li, H., Huang, H., Larose, L., Li, S. S.-C., Takano, T., et al. (2006) · Nature · doi:10.1038/nature04662 · Cited by 489
Self-citationGangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485
Luciani, A., Villella, V. R., Esposito, S., Brunetti-Pierri, N., Medina, D., Settembre, C., Gavina, M., Pulze, L., Giardino, I., Pettoello-Mantovani, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2090 · Cited by 467
Budde, K., Becker, T., Arns, W., Sommerer, C., Reinke, P., Eisenberger, U., Kramer, S., Fischer, W., Gschaidmeier, H., & Pietruck, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62318-5 · Cited by 359
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Ellen Jackson, C., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. (2007) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 342
Öst, A., Svensson, K., Ruishalme, I., Brännmark, C., Franck, N., Krook, H., Sandström, P., Kjolhede, P., & Strålfors, P. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00023 · Cited by 270
Eremina, V., Cui, S., Gerber, H., Ferrara, N., Haigh, J., Nagy, A., Ema, M., Rossant, J., Jothy, S., Miner, J. H., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080810 · Cited by 246
Self-citationDing, M., Cui, S., Li, C., Jothy, S., Haase, V., Steer, B. M., Marsden, P. A., Pippin, J., Shankland, S., Rastaldi, M. P., et al. (2006) · Nature Medicine · doi:10.1038/nm1460 · Cited by 212
Self-citationHigh Sirolimus Levels May Induce Focal Segmental Glomerulosclerosis De Novo
Letavernier, E., Bruneval, P., Mandet, C., Van Huyen, J.-P. D., Pe[Combining Acute Accent]raldi, M.-N. D., Helal, I., Noe[Combining Diaeresis]l, L.-H. A. A. G. A., & Legendre, C. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03751106 · Cited by 200
Sirolimus Therapy to Halt the Progression of ADPKD
Perico, N., Antiga, L., Caroli, A., Ruggenenti, P., Fasolini, G., Cafaro, M., Ondei, P., Rubis, N., Diadei, O., Gherardi, G., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121302 · Cited by 165
Sartelet, H., Toupance, O., Lorenzato, M., Fadel, F., Noël, L. H., Lagonotte, E., Birembaut, P. L., Chanard, J., & Rieu, P. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01047.x · Cited by 151
mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes
Vollenbröker, B., George, B., Wolfgart, M., Saleem, M. A., Pavenstädt, H., & Weide, T. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90319.2008 · Cited by 116
A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis
Tumlin, J. A., Miller, D., Near, M., Selvaraj, S., Hennigar, R., & Guasch, A. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00120605 · Cited by 71
Stallone, G., Infante, B., Pontrelli, P., Gigante, M., Montemurno, E., Loverre, A., Rossini, M., Schena, F. P., Grandaliano, G., & Gesualdo, L. (2011) · Transplantation · doi:10.1097/tp.0b013e318211d342 · Cited by 70
Tanak, H., & Yavuz, M. (2010) · Journal of Molecular Modeling · doi:10.1007/s00894-009-0539-5 · Cited by 66
Fabry disease: a morphologic study of 11 cases
Fischer, E. G., Moore, M. J., & Lager, D. J. (2006) · Modern Pathology · doi:10.1038/modpathol.3800634 · Cited by 65
Cui, S., Li, C.-J., Ema, M., Weinstein, J. J., & Quaggin, S. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005030278 · Cited by 51
Self-citationmTOR pathway inhibition in renal cell carcinoma
Marín, Á. P., Redondo, A., Arranz, E. E., Auñón, P., Fernández, B. C., & Barón, M. G. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.11.008 · Cited by 14
Cited by
Cell Biology and Pathology of Podocytes
Greka, A., & Mundel, P. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153238 · Cited by 518
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
Mitochondrial dysfunction in the pathophysiology of renal diseases
Che, R., Yuan, Y., Huang, S., & Zhang, A. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00571.2013 · Cited by 394
“However, suppressed autophagy by inhibition of mTOR maintains damaged mitochondria, also leading to proteinuria (22), which is highly suggestive of the double-edged sword effect of autophagy.”
BackgroundStrategies for the management of adverse events associated with mTOR inhibitors
Kaplan, B., Qazi, Y., & Wellen, J. R. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.03.002 · Cited by 322
“Many mechanisms have been proposed, including decreased VEGF synthesis and expression, resulting in podocyte injury and focal segmental glomerulosclerosis; dose-related alteration of podocyte slit diaphragm-associated protein structure and function, resulting in loss of podocyte structural integrity; and activation of…”
BackgroundImpaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy
Tagawa, A., Yasuda, M., Kume, S., Yamahara, K., Nakazawa, J., Chin-Kanasaki, M., Araki, H., Araki, S.-I., Koya, D., Asanuma, K., et al. (2016) · Diabetes · doi:10.2337/db15-0473 · Cited by 315
“Moreover, the deletion of a single gene that regulates lysosome function enhanced podocyte damage and proteinuria in mice (16,17).”
Background
Metadata
- Authors
- Cinà, D. P., Onay, T., Paltoo, A., Li, C., Maezawa, Y., De Arteaga, J., Jurisicova, A., & Quaggin, S. E.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Onay, Tuncer
- Paltoo, Aarti
- Li, Chengjin
- Maezawa, Yoshiro
- Jurisicova, Andrea
- Quaggin, Susan E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2012-03
- Volume
- 23
- Issue
- 3
- Pages
- 412-420
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC3294311
- OpenAlex
- W2130127620
- Cited by
- 172
- References
- 42
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 9 · 2020: 18 · 2019: 15 · 2018: 8 · 2017: 11 · 2016: 11 · 2015: 12 · 2014: 18 · 2013: 24 · 2012: 7
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP77756, MOP62931, TFF105268)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- mTOR inhibition, rapamycin, podocytes, autophagic flux, proteinuria, autophagosomes, autophagolysosomes, mitochondrial damage, end-stage renal disease, drug-induced nephrotoxicity
- MeSH terms
- Animals, Autophagy, Cells, Cultured, Disease Models, Animal, Humans, Lysosomes, Mice, Transgenic, Microtubule-Associated Proteins, Mitochondria, Proteinuria, Mice, Knockout, Sirolimus, Podocytes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.